Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance in Transplant-Ineligible Primary CNS Lymphoma (Phase 2, Open-label)
KCT0007409Phase 2Not yet recruiting
- Sponsor
- Yonsei University Health System
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in primary central nervous system lymphoma (PCNSL), diffuse large B-cell lymphoma (DLBCL), sponsored by Yonsei University Health System. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0007409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007409.